Targets › CD22
37 programs from 30 companies in 67 trials: 38 Phase 1, 25 Phase 2, 4 Phase 3; Oncology; next expected readout Dec 2026.
Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. (UniProt, P20273)
Open in Phaseline: the race on CD22, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Zhejiang University | CD19/CD22 CAR-T cells Bispecific CAR-T cell therapy targeting CD19 and CD22 | CD19, CD22 | Phase 2 | Large B-Cell Lymphoma (LBCL); ALL | Dec 2026 |
| Beijing Tongren Hospital | CD19/CD22-bispecific CAR-T cells bispecific CAR-T cell therapy targeting CD19 and CD22 | CD19, CD22 | Phase 2 | B-cell Acute Lymphoblastic Leukemia | Dec 2026 |
| Liping Dou | CD22/CD19 CAR-T cell immunotherapy Dual-targeted CAR-T cell therapy against CD19 and CD22 | CD22, CD19 | Phase 2 | Lymphoma | Jan 2027 |
| Daihong Liu | CD22/CD19 CAR-T cell immunotherapy CAR-T cell therapy targeting CD22 and CD19 | CD22, CD19 | Phase 2 | Lymphoma | Mar 2027 |
| Institute of Hematology & Blood Diseases Hospital, China | CAR-T cells (single-target or dual-target directed against CD19, CD20, and/or CD CAR-T cell therapy targeting CD19, CD20, and/or CD22 | CD19, CD20, CD22 | Phase 2 | Relapsed or Refractory Aggressive B-cell Lymphoma | May 2027 |
| The First Affiliated Hospital of Soochow University | CD22/CD19 CAR-T cells Dual-target CAR-T cells directed against CD22 and CD19 with 4-1BB co-stimulatory molecule | CD22, CD19 | Phase 2 | B-cell Acute Lymphoblastic Leukemia | Jul 2027 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | CD19&CD22 bispecific CAR-T cells Bispecific CAR-T cell therapy targeting CD19 and CD22 | CD19, CD22 | Phase 2 | B-cell Acute Lymphoblastic Leukemia; B-Cell Lymphoblastic Leukemia/Lymphoma | Dec 2027 |
| National Cancer Institute (NCI) | CD22 CAR-transduced T cells Anti-CD22 CAR-T cell therapy | CD22 | Phase 2 | Acute Lymphoblastic Leukemia | Jan 2030 |
| Pfizer | Inotuzumab ozogamicin CD22 binding agent | CD22 | Phase 2 | ACUTE LYMPHOBLASTIC LEUKEMIA; B Acute Lymphoblastic Leukemia; B-Cell Acute Lymphoblastic Leukaemia; Leukemia, Acute Lymphoblastic … | May 2033 |
| University of Colorado, Denver | CD19x22 CAR T Cells Dual-targeted CAR T cell therapy against CD19 and CD22 | CD19, CD22 | Phase 1 | Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia | Dec 2026 |
| Rong Tao | KQ-2002 CAR-T cells anti-CD19/CD22 CAR-T cell therapy | CD19, CD22 | Phase 1 | Acute Lymphoblastic Leukemia, in Relapse | Dec 2026 |
| Beijing GoBroad Hospital | Donor-derived CD22 CAR T cells CAR-T cell therapy targeting CD22 | CD22 | Phase 1 | B-cell Acute Lymphoblastic Leukemia | Dec 2026 |
| Ohio State University Comprehensive Cancer Center | Autologous Anti-CD19/CD20/CD22 CAR T-cells Multi-targeted CAR-T cell therapy targeting CD19, CD20, and CD22 | CD19, CD20, CD22 | Phase 1 | Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | Dec 2026 |
| Liping Dou | CD22/CD19 Dual-Target CAR-T Cells Dual-target CAR-T cell therapy targeting CD22 and CD19 antigens | CD22, CD19 | Phase 1 | B-cell Acute Lymphoblastic Leukemia | Dec 2026 |
| Peking University People's Hospital | Nanobody-Based CD19/CD22 Tandem Dual CAR-T Nanobody-based dual CAR-T cells targeting CD19 and CD22 | CD19, CD22 | Phase 1 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Dec 2026 |
| Essen Biotech | EB-BH2024 (CD19/CD22-CAR T cells) CD19/CD22-targeted chimeric antigen receptor T cells | CD19, CD22 | Phase 1 | Acute Lymphoblastic Leukemia, Adult B-Cell | Feb 2027 |
| Stanford University | CD22CART anti-CD22 CAR-T cell therapy | CD22 | Phase 1 | Leukemia; Follicular Lymphoma | Feb 2027 |
| University Hospital Tuebingen | MB-CART2219.1 CAR-T cell therapy targeting CD19 and CD22 | CD19, CD22 | Phase 1 | Lymphoma | Mar 2027 |
| Hebei Senlang Biotechnology | Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells Multi-target CAR-T cells targeting CD19, CD20, and CD22 | CD19, CD22, CD20 | Phase 1 | 19 and 22+ B Cell Hematologic Tumors | Mar 2027 |
| Sheba Medical Center | SHB-04-CD22 anti-CD22 CAR-T cell therapy | CD22 | Phase 1 | B Cell Malignancies | Apr 2027 |
| Sumithira Vasu | Anti-CD19/CD20/CD22 CAR T-Cells Multi-targeted CAR-T cell therapy targeting CD19, CD20, and CD22 | CD19, CD20, CD22 | Phase 1 | Recurrent Acute Lymphoblastic Leukemia | Jul 2027 |
| National Cancer Institute (NCI) | CD19/CD22-CAR-transduced T cells bicistronic CAR-T cell therapy targeting CD19 and CD22 | CD19, CD22 | Phase 1 | B-NHL | Jul 2027 |
| Cellectis | UCART20x22 Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptor | CD20, CD22 | Phase 1 | B-cell Non-Hodgkin Lymphoma (B-NHL) | Aug 2027 |
| Guangzhou Women and Children's Medical Center | CD19/CD22 CAR-T cell therapy Dual-target CAR-T cell therapy targeting CD19 and CD22 using retroviral vector-based tande | CD19, CD22 | Phase 1 | Acute Lymphoblastic Leukemia | Dec 2027 |
| Ruijin Hospital | Anti-CD19/CD22 Dual-Target Cord Blood CAR-T Cells Dual-targeted CAR-T cells expressing chimeric antigen receptors against CD19 and CD22 | CD19, CD22 | Phase 1 | B-cell Acute Lymphoblastic Leukemia | Mar 2028 |
| AstraZeneca | AZD4512 anti-CD22 antibody-drug conjugate | CD22 | Phase 1 | B-cell Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia (B-ALL) | Jul 2028 |
| National University Hospital, Singapore | CD22 CAR T CAR-T cell therapy targeting CD22 expressing B cell lymphoma cells | CD22 | Phase 1 | B-cell Lymphoma Refractory | Oct 2028 |
| National Cancer Institute (NCI) | Moxetumomab Pasudotox-tdfk CD22-directed recombinant immunotoxin (anti-CD22 antibody conjugated to Pseudomonas exotox | CD22 | Phase 1 | Hairy Cell Leukemia | Jun 2029 |
| St. Jude Children's Research Hospital | CD19-CD22 CAR T cell bispecific CAR T cell targeting CD19 and CD22 | CD19, CD22 | Phase 1 | Acute Lymphoblastic Leukemia | Jan 2030 |
| Instituto de Investigación Hospital Universitario La Paz | Autologous CD19/CD22 CAR T cells Anti-CD19/CD22 chimeric antigen receptor T cell therapy | CD19, CD22 | Phase 1 | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Jun 2030 |
| Umoja Biopharma | UB-VV400 CD22-directed CAR T cell therapy | CD22 | Phase 1 | Lymphoma, B Cell | Aug 2031 |
| Seattle Children's Hospital | Patient-derived CD19- and CD22 specific CAR T-cells Dual-specificity CAR-T cells targeting CD19 and CD22 | CD19, CD22 | Phase 1 | Leukemia | Mar 2035 |
| Stanford University | CD19/CD22 Chimeric Antigen Receptor T-Cell Therapy CAR T cell therapy targeting CD19 and CD22 | CD19, CD22 | Phase 1 | B Acute Lymphoblastic Leukemia | Aug 2035 |
| National Cancer Institute (NCI) | CD22CART cell infusion anti-CD22 chimeric antigen receptor T cell therapy | CD22 | Phase 1 | Hairy Cell Leukemia | Dec 2036 |
| Seattle Children's Hospital | SCRI-CAR22v2 anti-CD22 CAR-T cell therapy | CD22 | Phase 1 | Leukemia | Feb 2040 |
| Melody Smith | Allogeneic donor-derived CD19/CD22-CAR T cells bivalent CAR-T cell therapy targeting CD19 and CD22 | CD19, CD22 | Phase 1 | Lymphoid Leukemia | Dec 2045 |
| Cellectis | UCART22 Allogeneic engineered T-cells expressing anti-CD22 chimeric antigen receptor (CAR-T) | CD22 | Phase 1 | B-cell Acute Lymphoblastic Leukemia | – |
B-cell Acute Lymphoblastic Leukemia (11) Acute Lymphoblastic Leukemia (6) B Acute Lymphoblastic Leukemia (6) Lymphoma (4) Leukemia (4) ALL (2) Hairy Cell Leukemia (2) Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) Acute Lymphocytic Leukemia (2) Large B-Cell Lymphoma (LBCL) (1) Lymphoid Leukemia (1) Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (1)
other (17), mixed (11), protein or peptide (4), small molecule (3)
National Cancer Institute (NCI) (4) Liping Dou (2) Stanford University (2) Cellectis (2) Seattle Children's Hospital (2) Zhejiang University (1) Guangzhou Women and Children's Medical Center (1) Melody Smith (1) Peking University People's Hospital (1) AstraZeneca (1) Sheba Medical Center (1) Beijing Tongren Hospital (1) Institute of Hematology & Blood Diseases Hospital, China (1) Pfizer (1) University of Colorado, Denver (1) St. Jude Children's Research Hospital (1) Umoja Biopharma (1) The First Affiliated Hospital of Soochow University (1) Sumithira Vasu (1) Rong Tao (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.